A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Overview of attention for article published in Frontiers in Medicine, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 6 publications that cite this research output.

6

The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Article in Hepatology Research (January 2024)

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches

Article in Journal of Pharmacy & Pharmaceutical Sciences (November 2023)

Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy

Article in Molecular Metabolism (September 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.